A team at the University of Kansas School of Medicine has identified a potential target for treating breast cancer, including a particularly deadly form of the disease.
So-called “triple-negative” breast cancer represents between 12 and 17 percent of all breast cancers. It derives its name from the lack of receptors for estrogen, progesterone and Her2. The absence of these receptors rules out proven hormone therapies such as tamoxifen. Triple-negative breast cancer can be more aggressive and is more likely to recur than other breast cancers.
Because of the lack of existing therapies, the KU team chose to examine a member of a family of protein kinase enzymes. In recent years, atypical protein kinase C signaling has been found in the tissue invasion and metastasis of multiple tumors.
The research team, including Soumen Paul, Ph.D., associate professor, Arindam Paul, Ph.D., assistant professor, and Ossama Tawfik, professor, M.D., Ph. D., all in the Department of Pathology and Laboratory Medicine, and their colleagues, studied atypical protein kinase c lambda/iota signaling during the invasive progression of triple negative breast cancer. Among other tests, they looked at tissue samples of breast cancer that had spread to the liver, lung and other organs. They found that atypical protein kinase c lambda/iota, which is known to influence cell growth, was highly expressed and phosphorylated in metastatic breast cancers.
Previous studies, Soumen Paul said, had implicated the atypical protein kinase c lambda/iota in the other carcinomas. But no prior study had indicated any role in breast cancer metastasis. In a recent paper, published in the journal Cell Death and Differentiation, Paul and his colleagues conclude that atypical protein kinase c lambda/iota holds “tremendous” promise for treating breast cancer.
“We have been able to show that this protein is highly expressed in metastatic triple-negative breast cancer, and when we are depleting it from triple-negative breast cancer cells, we found that the cancer cells are not metastasizing,” Paul said. “The tumor growth is slowing down. This is giving us an opportunity for a targeted therapy.”